Login to Your Account



New, Quicker Approval Path

Pharmacyclics, J&J's Ibrutinib Wins FDA 'Breakthrough' Tag

By Randy Osborne
Staff Writer

Thursday, February 14, 2013
Pharmacyclics Inc., with partner Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, became the latest in a small handful of companies to gain "breakthrough therapy designation," a new category that could let drug developers win approval of their drug candidates based on single, Phase I trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription